US OptionsDetailed Quotes

ARMP241220P2500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 20 09:30 ET

0.00High0.00Low

Armata Pharmaceuticals Stock Discussion

Jaguar8

Dec 19 06:06

NEWS

$Armata Pharmaceuticals (ARMP.US)$
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Thursday, 19th December at 7:00 am
Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Armata Pharmaceutic...

Jaguar8

Nov 14 15:33

13D

$Armata Pharmaceuticals (ARMP.US)$
Armata Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Innoviva, Inc(85.2%),Innoviva Strategic Opportunities LLC(62.1%)

Jaguar8

Nov 12 06:06

NEWS

$Armata Pharmaceuticals (ARMP.US)$
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025
LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology compan...

Trytosaveabit

Aug 14 05:42

Watching for data!

$Armata Pharmaceuticals (ARMP.US)$ The last patient had their final follow-up visit on August 7th, in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. Armata anticipates topline data from the Tailwind study in the second half of 2024.

Trytosaveabit

Jul 30 06:06

Update

$Armata Pharmaceuticals (ARMP.US)$ Reuters· 5 mins ago
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding From the U.S. Department of Defense to Support Ongoing Disarm Clinical Trial of AP-SA02

The Thinker

Jul 17 19:52

Dow Hits Record High as Tech Stocks Tumble

Follow Our Official Telegram Channel tynkrlab
$Dow Jones Industrial Average (.DJI.US)$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index (.SPX.US)$ fell by 1.39%, and the $Nasdaq Composite Index (.IXIC.US)$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth (UNH.US)$, $Johnson & Johnson (JNJ.US)$, and $Cisco (CSCO.US)$ l...

Trytosaveabit

Jul 11 06:06

Update! Note the dates. Especially phase 2 data release.

$Armata Pharmaceuticals (ARMP.US)$ Armata Pharmaceuticals Inc -Phase 2 Topline Data Anticipated in 2H 2024 Followed by Potential Initiation of a Pivotal Bronchiectasis Trial in 2025

Trytosaveabit

Nov 15, 2023 05:32

Watching For 2 reasons!

$Armata Pharmaceuticals (ARMP.US)$ Armata has shown a rapid enrollment rate in the Phase 2a portion of the diSArm study, which tests AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Furthermore, the company is making strides in the Phase 2 Tailwind study of AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with Pseudomonas aeruginosa lung infections.
The second reason for is Armata’s diligence in preparing for future studies. The company i...

Alvinnnnnnngenius

May 22, 2023 02:37

Safe play for beginners bottoms loading here

$Armata Pharmaceuticals (ARMP.US)$
$NN Inc (NNBR.US)$ AH up 12% may look for lower entry or risk management will help

No comment yet